Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations.

Gemma BurdgeAlice HardmanIsabel CarberyGiacomo BroglioDan GreerChristian Philipp Selinger

Published in: Journal of clinical medicine (2022)

Switch uptake rates were 58%, with 90% of patients eligible to switch. Switch decision was influenced by time savings for patients but not by other patient-related factors.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
high dose
low dose
ulcerative colitis